Novartis scoops up rights to NASH drug

4th May 2017 Uncategorised 0

Novartis has exercised an option giving it global development and commercialisation rights to an experimental drug being developed by US biotech Conatus for nonalcoholic steatohepatitis (NASH), a progressive form of non-alcoholic fatty liver disease.

More: Novartis scoops up rights to NASH drug
Source: News